Ziconotide vs Somatostatin
Head-to-head comparison of Ziconotide (ω-Conotoxin MVIIA (ziconotide)) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Ziconotide | Somatostatin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | ω-Conotoxin MVIIA (ziconotide) | Somatostatin-14 |
| Molecular Weight | 2639.1 Da | 1637.85 |
| Half-Life | approximately 4.5 hours | 1-3 min |
| Amino Acids | 25 | 14 |
| Typical Dose | 0.5-19.2 mcg/day | N/A|N/A |
| Route | Intrathecal | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 500 | 84 |
| Research Status | Approved | Approved |
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Somatostatin Dosing
N/A|N/A
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.